% Expired Patents = 9.5

EPO Patents = 1

Forward Citations = 25

Loading Chart...

3 inventors (with patents filed for the assignee):

Yi Heng Chen (16 out of 77 patents)

Yan Lou (11 out of 74 patents)

Yi Chen (5 out of 5 patents)

4. Xiang Li (14 patents)

21 patents: Sort by Forward Citations

1. 12747251 - Inhibitor of BTK and mutants thereof (2026-09-29),

2. 12637467 - INHIBITOR OF BTK AND MUTANTS THEREOF (2026-05-26),

3. 12583853 - 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES (2026-03-24),

4. 12569564 - Spirocyclic MDM2 modulator and uses thereof (2026-03-10),

5. 12552784 - 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases (2026-02-17),

6. 12410190 - Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases (2025-09-09),

7. 12220419 - BCL-2 inhibitors (2025-02-11),

8. 12086788 - Substituted pyrazines as inhibitors of BTK, and mutants thereof (2024-09-10),

9. 11993610 - BCL-2 inhibitors (2024-05-28),

10. 11903950 - BCL-2 inhibitors (2024-02-20),

11. 11680072 - Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases (2023-06-20),

12. 11501284 - Substituted pyrazines as inhibitors of BTK, and mutants thereof (2022-11-15),

13. 11479555 - Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase (2022-10-25),

14. 11365206 - BCL-2 inhibitors (2022-06-21),

15. 11279711 - Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases (2022-03-22),

Company Overview

Newave Pharmaceutical Inc. is a biotechnology company based in Pleasanton, California, specializing in the development and manufacturing of innovative pharmaceutical products. The organization focuses on advancing therapies in various therapeutic areas, leveraging cutting-edge research and technology to address unmet medical needs. With a commitment to quality and efficacy, Newave aims to enhance patient outcomes through its robust pipeline of drug candidates and strategic collaborations within the healthcare sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

21 Patents

#32 in Pleasanton, CA

#3,760 in California

#15,695 in US

#29,961 in the World

Pleasanton, CA, United States of America

Newave Pharmaceutical Inc.

Forward Citations = 25

3 inventors:

Yi Heng Chen (16 out of 77 patents)

Yan Lou (11 out of 74 patents)

Yi Chen (5 out of 5 patents)

4. Xiang Li (14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Newave Pharmaceutical Inc.. Retrieved from https://idiyas.com/company/newave-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]